RECENT FUNDING ROUNDS
| Company | Country | Profile | Funding round | Value | Date | |
|---|---|---|---|---|---|---|
|
Neurelis Inc | Neuroscience company. | Series D | USD 114,000,000 | ||
|
Maridose LLC | Biotech - Cannabis R&D. We are a US DEA licensed manufacturer of Schedule 1 drugs. | Pre Seed | USD 150,000 | ||
|
Gilgamesh Pharmaceuticals Inc | Novel psychedelic-Inspired therapeutics for treating mental illness. | Seed | |||
|
3-V Biosciences Inc | Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. | Series B | USD 30,000,000 | ||
|
Vyome Biosciences Pvt Ltd | Developer of medicines for treating skin diseases caused by resistant microbes. | Series C | USD 14,000,000 | ||
|
Arcis Biotechnology Holdings Ltd | N/A | GBP 2,500,000 | |||
|
FunkSac LLC | Provider of customer services and compliant packaging solutions for the legal cannabis industry; both medical and recreational markets. | N/A | |||
|
23andMe Inc | DNA testing and genome sequencing firm. | Series E | USD 79,100,000 | ||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
3SBio Inc | IPO | HKD 5,510,000,000 | |||
|
|
23andMe Inc | DNA testing and genome sequencing firm. | Grant | USD 1,400,000 | ||
|
Merck & Co | Acquisition | USD 14,200,000,000 | |||
|
|
Arecor Ltd | Developer of technology that is used in the formulation of biopharmaceuticals. | N/A | |||
|
|
Zosano Pharma Inc | Debt | USD 3,030,000 | |||
|
|
3-V Biosciences Inc | Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases. | Series C | USD 20,000,000 | ||
|
|
Tokai Pharmaceuticals Inc | Developer of prostate cancer drugs | Series E | USD 35,000,000 | ||
|
|
Trevena Inc | Series C | USD 60,000,000 | |||
|
|
Allecra Therapeutics | Developer of antibiotic treatments designed to combat multi drug-resistant gram-negative bacteria | Series A | EUR 15,000,000 | ||
|
|
Aquinox Pharmaceuticals Inc | Developer of small molecule therapeutics for the treatment of inflammatory disease | Series C | |||
|
|
Aquinox Pharmaceuticals Inc | Developer of small molecule therapeutics for the treatment of inflammatory disease | Series C | USD 18,000,000 | ||
|
|
Kala Pharmaceuticals Inc | Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases | Series A |
MOST ACTIVE INVESTORS
MOST ACTIVE ACQURERS
| Pfizer Inc | US | 6 |
| Ampersand Ventures | US | 3 |
| Gilead Sciences Inc | US | 3 |
| Abbott Laboratories | US | 2 |
| F Hoffmann-La Roche Ltd | 1 | |
| Emerging Capital Partners | US | 1 |
| Allscripts Healthcare Solutions Inc | US | 1 |
| Johnson & Johnson Innovation LLC | US | 1 |
| Biogen Idec Inc | US | 1 |
| GelTex Pharmaceuticals | US | 1 |
| Pharmion Corp | US | 1 |
| Corixa Corp | US | 1 |
| Serologicals Corp | US | 1 |
| Viatris | 1 | |
| Bayer AG | DE | 1 |
| Vets First Choice | 1 | |
| Baxter International Inc | US | 1 |
| Cubist Pharmaceuticals Inc | 1 | |
| Biovitrum AB | SE | 1 |
| Genzyme Corp | US | 1 |
| Galapagos NV | BE | 1 |
| Aquila Biopharmaceuticals Inc | 1 |
BEST FUNDED STARTUPS
Biopharmaceutical company discovering and developing novel therapeutics for the treatment of infectious diseases.
Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.
![[current-page:title] logo](/sites/default/files/styles/thumbnail/public/default_images/_no-logo.png?itok=xgKd-YA_){kind=logo}
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.
Developer of small molecule therapeutics for the treatment of inflammatory disease
Developer of products that penetrate the mucosal barrier to treat a variety of severe diseases
Developer of medicines for treating skin diseases caused by resistant microbes.
Developer of antibodies to reduce tissue damage and improve ventricular function associated with myocardial infarction